schliessen

Filtern

 

Bibliotheken

Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis.

AIMTo compare the efficacy of the sole intravitreal triamcinolone (IVT) versus intravitreal bevacizumab (IVB) alone or IVB combined with IVT in the treatment of diabetic macular edema (DME). METHODSPertinent publications were identified through systematic searches of database and manually searching.... Full description

Journal Title: International journal of ophthalmology 2013, Vol.6(4), pp.546-552
Main Author: Zhang, Xiao-Ling
Other Authors: Chen, Jian , Zhang, Ri-Jia , Wang, Wen-Jie , Zhou, Qing , Qin, Xiao-Yan
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 2222-3959 ; DOI: 10.3980/j.issn.2222-3959.2013.04.26
Link: http://search.proquest.com/docview/1429216442/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest1429216442
title: Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis.
format: Article
creator:
  • Zhang, Xiao-Ling
  • Chen, Jian
  • Zhang, Ri-Jia
  • Wang, Wen-Jie
  • Zhou, Qing
  • Qin, Xiao-Yan
subjects:
  • Bevacizumab
  • Diabetic Macular Edema
  • Meta-Analysis
  • Triamcinolone
ispartof: International journal of ophthalmology, 2013, Vol.6(4), pp.546-552
description: AIMTo compare the efficacy of the sole intravitreal triamcinolone (IVT) versus intravitreal bevacizumab (IVB) alone or IVB combined with IVT in the treatment of diabetic macular edema (DME). METHODSPertinent publications were identified through systematic searches of database and manually searching. Methodological quality of the literatures was valuated according to the Jadad Score. RevMan 5.1.0 was used to do the meta-analysis. Heterogeneity was determined and sensitivity was conducted. RESULTSSix studies were ultimately included in the meta-analysis. The results of our analysis showed IVT had a statistically significant improvement in vision over the IVB at 1 month and 3 months (P
language: eng
source:
identifier: ISSN: 2222-3959 ; DOI: 10.3980/j.issn.2222-3959.2013.04.26
fulltext: fulltext
issn:
  • 22223959
  • 2222-3959
url: Link


@attributes
ID1399910600
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid1429216442
sourceidproquest
recordidTN_proquest1429216442
sourcesystemPC
pqid1429216442
display
typearticle
titleIntravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis.
creatorZhang, Xiao-Ling ; Chen, Jian ; Zhang, Ri-Jia ; Wang, Wen-Jie ; Zhou, Qing ; Qin, Xiao-Yan
contributorZhang, Xiao-Ling (correspondence author) ; Zhang, Xiao-Ling (record owner)
ispartofInternational journal of ophthalmology, 2013, Vol.6(4), pp.546-552
identifierISSN: 2222-3959 ; DOI: 10.3980/j.issn.2222-3959.2013.04.26
subjectBevacizumab ; Diabetic Macular Edema ; Meta-Analysis ; Triamcinolone
descriptionAIMTo compare the efficacy of the sole intravitreal triamcinolone (IVT) versus intravitreal bevacizumab (IVB) alone or IVB combined with IVT in the treatment of diabetic macular edema (DME). METHODSPertinent publications were identified through systematic searches of database and manually searching. Methodological quality of the literatures was valuated according to the Jadad Score. RevMan 5.1.0 was used to do the meta-analysis. Heterogeneity was determined and sensitivity was conducted. RESULTSSix studies were ultimately included in the meta-analysis. The results of our analysis showed IVT had a statistically significant improvement in vision over the IVB at 1 month and 3 months (P<0.01). However, the reduction was not significant regarding central macular thickness (CMT) during the earlier (1 month and 3 months) follow-up period (P=0.12, P=0.41, respectively). At later visit (6 months), IVT had a significant decrease in CMT when compared to IVB (P<0.01) while no significant improvement in visual acuity (VA) was observed (P=0.14). The incidence of intraocular hypertension was 13/102 in IVT group during follow-up period while 0/103 in IVB group. The difference was significant (P<0.01). With regards to IVT versus IVB combined with IVT, there were no significant differences in CMT at 1 month (P=0.86) and 3 months (P=0.06). The incidence of intraocular hypertension was 6/67 in IVT group during follow-up period while 4/66 in IVB+IVT group. But the difference was not significant (P=0.53). CONCLUSIONCurrent evidence shows IVT is superior in improving VA at earlier follow-up (1 month and 3 months) and in reducing CMT at later follow-up (6 months) for DME. At other time, it is in favor of IVT treatment but there are no statistically significances. However, IVT has the side-effect of ocular hypertension. There is no adequate evidence of the benefit adding IVB to IVT in contrast to IVT alone.
languageeng
source
version3
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/1429216442/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Zhang, Xiao-Ling
1Chen, Jian
2Zhang, Ri-Jia
3Wang, Wen-Jie
4Zhou, Qing
5Qin, Xiao-Yan
titleIntravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis.
descriptionAIMTo compare the efficacy of the sole intravitreal triamcinolone (IVT) versus intravitreal bevacizumab (IVB) alone or IVB combined with IVT in the treatment of diabetic macular edema (DME). METHODSPertinent publications were identified through systematic searches of database and manually searching. Methodological quality of the literatures was valuated according to the Jadad Score. RevMan 5.1.0 was used to do the meta-analysis. Heterogeneity was determined and sensitivity was conducted. RESULTSSix studies were ultimately included in the meta-analysis. The results of our analysis showed IVT had a statistically significant improvement in vision over the IVB at 1 month and 3 months (P<0.01). However, the reduction was not significant regarding central macular thickness (CMT) during the earlier (1 month and 3 months) follow-up period (P=0.12, P=0.41, respectively). At later visit (6 months), IVT had a significant decrease in CMT when compared to IVB (P<0.01) while no significant improvement in visual acuity (VA) was observed (P=0.14). The incidence of intraocular hypertension was 13/102 in IVT group during follow-up period while 0/103 in IVB group. The difference was significant (P<0.01). With regards to IVT versus IVB combined with IVT, there were no significant differences in CMT at 1 month (P=0.86) and 3 months (P=0.06). The incidence of intraocular hypertension was 6/67 in IVT group during follow-up period while 4/66 in IVB+IVT group. But the difference was not significant (P=0.53). CONCLUSIONCurrent evidence shows IVT is superior in improving VA at earlier follow-up (1 month and 3 months) and in reducing CMT at later follow-up (6 months) for DME. At other time, it is in favor of IVT treatment but there are no statistically significances. However, IVT has the side-effect of ocular hypertension. There is no adequate evidence of the benefit adding IVB to IVT in contrast to IVT alone.
subject
0Bevacizumab
1Diabetic Macular Edema
2Meta-Analysis
3Triamcinolone
4bevacizumab
5diabetic macular edema
6meta-analysis
7triamcinolone
general
0English
110.3980/j.issn.2222-3959.2013.04.26
2MEDLINE (ProQuest)
3ProQuest Biological Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
11Biological Science Index (ProQuest)
sourceidproquest
recordidproquest1429216442
issn
022223959
12222-3959
rsrctypearticle
creationdate2013
addtitleInternational journal of ophthalmology
searchscope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
scope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
lsr43
01007527false
11007944false
21009130false
310000004false
410000038false
510000050false
610000120false
710000159false
810000238false
910000253false
1010000260false
1110000270false
1210000271false
1310000302false
1410000350false
contributorZhang, Xiao-Ling
startdate20130101
enddate20130101
citationpf 546 pt 552 vol 6 issue 4
lsr30VSR-Enriched:[pqid, eissn]
sort
titleIntravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis.
authorZhang, Xiao-Ling ; Chen, Jian ; Zhang, Ri-Jia ; Wang, Wen-Jie ; Zhou, Qing ; Qin, Xiao-Yan
creationdate20130101
lso0120130101
facets
frbrgroupid5889248435939818675
frbrtype5
newrecords20181218
languageeng
creationdate2013
topic
0Bevacizumab
1Diabetic Macular Edema
2Meta-Analysis
3Triamcinolone
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
9Biological Science Index (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Zhang, Xiao-Ling
1Chen, Jian
2Zhang, Ri-Jia
3Wang, Wen-Jie
4Zhou, Qing
5Qin, Xiao-Yan
jtitleInternational journal of ophthalmology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Zhang
1Chen
2Wang
3Zhou
4Qin
aufirst
0Xiao-Ling
1Jian
2Ri-Jia
3Wen-Jie
4Qing
5Xiao-Yan
au
0Zhang, Xiao-Ling
1Chen, Jian
2Zhang, Ri-Jia
3Wang, Wen-Jie
4Zhou, Qing
5Qin, Xiao-Yan
addauZhang, Xiao-Ling
atitleIntravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis.
jtitleInternational journal of ophthalmology
risdate20130101
volume6
issue4
spage546
epage552
pages546-552
issn2222-3959
formatjournal
genrearticle
ristypeJOUR
abstractAIMTo compare the efficacy of the sole intravitreal triamcinolone (IVT) versus intravitreal bevacizumab (IVB) alone or IVB combined with IVT in the treatment of diabetic macular edema (DME). METHODSPertinent publications were identified through systematic searches of database and manually searching. Methodological quality of the literatures was valuated according to the Jadad Score. RevMan 5.1.0 was used to do the meta-analysis. Heterogeneity was determined and sensitivity was conducted. RESULTSSix studies were ultimately included in the meta-analysis. The results of our analysis showed IVT had a statistically significant improvement in vision over the IVB at 1 month and 3 months (P<0.01). However, the reduction was not significant regarding central macular thickness (CMT) during the earlier (1 month and 3 months) follow-up period (P=0.12, P=0.41, respectively). At later visit (6 months), IVT had a significant decrease in CMT when compared to IVB (P<0.01) while no significant improvement in visual acuity (VA) was observed (P=0.14). The incidence of intraocular hypertension was 13/102 in IVT group during follow-up period while 0/103 in IVB group. The difference was significant (P<0.01). With regards to IVT versus IVB combined with IVT, there were no significant differences in CMT at 1 month (P=0.86) and 3 months (P=0.06). The incidence of intraocular hypertension was 6/67 in IVT group during follow-up period while 4/66 in IVB+IVT group. But the difference was not significant (P=0.53). CONCLUSIONCurrent evidence shows IVT is superior in improving VA at earlier follow-up (1 month and 3 months) and in reducing CMT at later follow-up (6 months) for DME. At other time, it is in favor of IVT treatment but there are no statistically significances. However, IVT has the side-effect of ocular hypertension. There is no adequate evidence of the benefit adding IVB to IVT in contrast to IVT alone.
doi10.3980/j.issn.2222-3959.2013.04.26
urlhttp://search.proquest.com/docview/1429216442/
eissn22274898
date2013-01-01